Sino Biopharmaceutical (OTCMKTS:SBMFF) Reaches New 12-Month High - Here's What Happened

Key Points

• Sino Biopharmaceutical shares reached a new 52-week high at $0.99, rising from a previous close of $0.95, with a trading volume of 132 shares.
• The company has shown a significant increase of 4.1% on its stock, reflecting positive trading momentum.
• Sino Biopharmaceutical operates as a pharmaceutical conglomerate in China, focusing on oncology, liver disease, and respiratory medicines.

Sino Biopharmaceutical (OTCMKTS:SBMFF - Get Free Report) reached a new 52-week high during trading on Wednesday . The company traded as high as $0.99 and last traded at $0.99, with a volume of 132 shares traded. The stock had previously closed at $0.95.

Sino Biopharmaceutical Price Performance

The business has a fifty day moving average of $0.79 and a 200 day moving average of $0.57.

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.